A translation inhibitor that suppresses dengue virus in vitro and in vivo

Qing Yin Wang, Ravinder Reddy Kondreddi, Xuping Xie, Ranga Rao, Shahul Nilar, Hao Ying Xu, Min Qing, David Chang, Hongping Dong, Fumiaki Yokokawa, Suresh B. Lakshminarayana, Anne Goh, Wouter Schul, Laura Kramer, Thomas H. Keller, Pei-Yong Shi

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

We describe a novel translation inhibitor that has anti-dengue virus (DENV) activity in vitro and in vivo. The inhibitor was identified through a high-throughput screening using a DENV infection assay. The compound contains a benzomorphan core structure. Mode-of-action analysis indicated that the compound inhibits protein translation in a viral RNA sequence-independent manner. Analysis of the stereochemistry demonstrated that only one enantiomer of the racemic compound inhibits viral RNA translation. Medicinal chemistry was performed to eliminate a metabolically labile glucuronidation site of the compound to improve its in vivo stability. Pharmacokinetic analysis showed that upon a single subcutaneous dosing of 25 mg/kg of body weight in mice, plasma levels of the compound reached a Cmax (maximum plasma drug concentration) above the protein-binding-adjusted 90% effective concentration (EC90) value of 0.96 μM. In agreement with the in vivo pharmacokinetic results, treatment of DENV-infected mice with 25 mg/kg of compound once per day reduced peak viremia by about 40-fold. However, mice treated with 75 mg/kg of compound per day exhibited adverse effects. Collectively, our results demonstrate that the benzomorphan compounds inhibit DENV through suppression of RNA translation. The therapeutic window of the current compounds needs to be improved for further development.

Original languageEnglish (US)
Pages (from-to)4072-4080
Number of pages9
JournalAntimicrobial Agents and Chemotherapy
Volume55
Issue number9
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Dengue Virus
Benzomorphans
Viral RNA
Pharmacokinetics
Pharmaceutical Chemistry
Viremia
Protein Biosynthesis
Virus Diseases
Protein Binding
Body Weight
RNA
In Vitro Techniques
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

A translation inhibitor that suppresses dengue virus in vitro and in vivo. / Wang, Qing Yin; Kondreddi, Ravinder Reddy; Xie, Xuping; Rao, Ranga; Nilar, Shahul; Xu, Hao Ying; Qing, Min; Chang, David; Dong, Hongping; Yokokawa, Fumiaki; Lakshminarayana, Suresh B.; Goh, Anne; Schul, Wouter; Kramer, Laura; Keller, Thomas H.; Shi, Pei-Yong.

In: Antimicrobial Agents and Chemotherapy, Vol. 55, No. 9, 09.2011, p. 4072-4080.

Research output: Contribution to journalArticle

Wang, QY, Kondreddi, RR, Xie, X, Rao, R, Nilar, S, Xu, HY, Qing, M, Chang, D, Dong, H, Yokokawa, F, Lakshminarayana, SB, Goh, A, Schul, W, Kramer, L, Keller, TH & Shi, P-Y 2011, 'A translation inhibitor that suppresses dengue virus in vitro and in vivo', Antimicrobial Agents and Chemotherapy, vol. 55, no. 9, pp. 4072-4080. https://doi.org/10.1128/AAC.00620-11
Wang, Qing Yin ; Kondreddi, Ravinder Reddy ; Xie, Xuping ; Rao, Ranga ; Nilar, Shahul ; Xu, Hao Ying ; Qing, Min ; Chang, David ; Dong, Hongping ; Yokokawa, Fumiaki ; Lakshminarayana, Suresh B. ; Goh, Anne ; Schul, Wouter ; Kramer, Laura ; Keller, Thomas H. ; Shi, Pei-Yong. / A translation inhibitor that suppresses dengue virus in vitro and in vivo. In: Antimicrobial Agents and Chemotherapy. 2011 ; Vol. 55, No. 9. pp. 4072-4080.
@article{e47e02f802974671985c1c51e9faef2f,
title = "A translation inhibitor that suppresses dengue virus in vitro and in vivo",
abstract = "We describe a novel translation inhibitor that has anti-dengue virus (DENV) activity in vitro and in vivo. The inhibitor was identified through a high-throughput screening using a DENV infection assay. The compound contains a benzomorphan core structure. Mode-of-action analysis indicated that the compound inhibits protein translation in a viral RNA sequence-independent manner. Analysis of the stereochemistry demonstrated that only one enantiomer of the racemic compound inhibits viral RNA translation. Medicinal chemistry was performed to eliminate a metabolically labile glucuronidation site of the compound to improve its in vivo stability. Pharmacokinetic analysis showed that upon a single subcutaneous dosing of 25 mg/kg of body weight in mice, plasma levels of the compound reached a Cmax (maximum plasma drug concentration) above the protein-binding-adjusted 90{\%} effective concentration (EC90) value of 0.96 μM. In agreement with the in vivo pharmacokinetic results, treatment of DENV-infected mice with 25 mg/kg of compound once per day reduced peak viremia by about 40-fold. However, mice treated with 75 mg/kg of compound per day exhibited adverse effects. Collectively, our results demonstrate that the benzomorphan compounds inhibit DENV through suppression of RNA translation. The therapeutic window of the current compounds needs to be improved for further development.",
author = "Wang, {Qing Yin} and Kondreddi, {Ravinder Reddy} and Xuping Xie and Ranga Rao and Shahul Nilar and Xu, {Hao Ying} and Min Qing and David Chang and Hongping Dong and Fumiaki Yokokawa and Lakshminarayana, {Suresh B.} and Anne Goh and Wouter Schul and Laura Kramer and Keller, {Thomas H.} and Pei-Yong Shi",
year = "2011",
month = "9",
doi = "10.1128/AAC.00620-11",
language = "English (US)",
volume = "55",
pages = "4072--4080",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "9",

}

TY - JOUR

T1 - A translation inhibitor that suppresses dengue virus in vitro and in vivo

AU - Wang, Qing Yin

AU - Kondreddi, Ravinder Reddy

AU - Xie, Xuping

AU - Rao, Ranga

AU - Nilar, Shahul

AU - Xu, Hao Ying

AU - Qing, Min

AU - Chang, David

AU - Dong, Hongping

AU - Yokokawa, Fumiaki

AU - Lakshminarayana, Suresh B.

AU - Goh, Anne

AU - Schul, Wouter

AU - Kramer, Laura

AU - Keller, Thomas H.

AU - Shi, Pei-Yong

PY - 2011/9

Y1 - 2011/9

N2 - We describe a novel translation inhibitor that has anti-dengue virus (DENV) activity in vitro and in vivo. The inhibitor was identified through a high-throughput screening using a DENV infection assay. The compound contains a benzomorphan core structure. Mode-of-action analysis indicated that the compound inhibits protein translation in a viral RNA sequence-independent manner. Analysis of the stereochemistry demonstrated that only one enantiomer of the racemic compound inhibits viral RNA translation. Medicinal chemistry was performed to eliminate a metabolically labile glucuronidation site of the compound to improve its in vivo stability. Pharmacokinetic analysis showed that upon a single subcutaneous dosing of 25 mg/kg of body weight in mice, plasma levels of the compound reached a Cmax (maximum plasma drug concentration) above the protein-binding-adjusted 90% effective concentration (EC90) value of 0.96 μM. In agreement with the in vivo pharmacokinetic results, treatment of DENV-infected mice with 25 mg/kg of compound once per day reduced peak viremia by about 40-fold. However, mice treated with 75 mg/kg of compound per day exhibited adverse effects. Collectively, our results demonstrate that the benzomorphan compounds inhibit DENV through suppression of RNA translation. The therapeutic window of the current compounds needs to be improved for further development.

AB - We describe a novel translation inhibitor that has anti-dengue virus (DENV) activity in vitro and in vivo. The inhibitor was identified through a high-throughput screening using a DENV infection assay. The compound contains a benzomorphan core structure. Mode-of-action analysis indicated that the compound inhibits protein translation in a viral RNA sequence-independent manner. Analysis of the stereochemistry demonstrated that only one enantiomer of the racemic compound inhibits viral RNA translation. Medicinal chemistry was performed to eliminate a metabolically labile glucuronidation site of the compound to improve its in vivo stability. Pharmacokinetic analysis showed that upon a single subcutaneous dosing of 25 mg/kg of body weight in mice, plasma levels of the compound reached a Cmax (maximum plasma drug concentration) above the protein-binding-adjusted 90% effective concentration (EC90) value of 0.96 μM. In agreement with the in vivo pharmacokinetic results, treatment of DENV-infected mice with 25 mg/kg of compound once per day reduced peak viremia by about 40-fold. However, mice treated with 75 mg/kg of compound per day exhibited adverse effects. Collectively, our results demonstrate that the benzomorphan compounds inhibit DENV through suppression of RNA translation. The therapeutic window of the current compounds needs to be improved for further development.

UR - http://www.scopus.com/inward/record.url?scp=80051806465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051806465&partnerID=8YFLogxK

U2 - 10.1128/AAC.00620-11

DO - 10.1128/AAC.00620-11

M3 - Article

C2 - 21730119

AN - SCOPUS:80051806465

VL - 55

SP - 4072

EP - 4080

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 9

ER -